Can we predict thrombotic tendency in rheumatoid arthritis? A thromboelastographic analysis (with ROTEM)


Turk S. M., ÜSKÜDAR CANSU D., ÜSKÜDAR TEKE H., KAŞİFOĞLU T., Akay O. M., BİLGİN M., ...More

CLINICAL RHEUMATOLOGY, vol.37, no.9, pp.2341-2349, 2018 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 37 Issue: 9
  • Publication Date: 2018
  • Doi Number: 10.1007/s10067-018-4134-y
  • Journal Name: CLINICAL RHEUMATOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.2341-2349
  • Keywords: Rotational thromboelastography, Rheumatoid arthritis, Thromboelastography, Thrombosis, NONCARDIAC VASCULAR-DISEASE, CARDIOVASCULAR RISK-FACTORS, C-REACTIVE PROTEIN, VENOUS THROMBOEMBOLISM, EVENTS, INFLAMMATION, POPULATION, MORTALITY, GLUCOCORTICOIDS, THERAPY
  • Eskisehir Osmangazi University Affiliated: Yes

Abstract

The higher incidence of arterial and venous events is well established in patients with rheumatoid arthritis (RA). Our aim here was to investigate whether there is a prothrombotic state in RA patients by using rotational thromboelastometry (ROTEM) method and to demonstrate whether the disease variables play a role in this process. A total of 85 patients who met the 2010 RA classification criteria were consecutively included in the study. The patients with RA who have been using antiaggregant, anticoagulant, or nonsteroidal anti-inflammatory drugs (NSAIDs) and had a history of arterial or venous thromboembolism were excluded from the study. Their complete blood count (CBC), erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), fibrinogen, D-dimer, and lipid profiles were measured, DAS-28 disease activation scores were calculated, and simultaneous ROTEM analysis was performed to determine the predisposition to thrombosis. Of the ROTEM parameters, clotting time (CT, seconds (s)), clot formation time (CFT, s), and maximum clot firmness (MCF) were evaluated. Having a shorter CT and/or CFT in intrinsic (I) or extrinsic (E) pathway and/or a longer MCF compared to the healthy controls was considered as "predisposition to hypercoagulability". The mean age of the 85 RA patients were 54.12 +/- 13 years, and 77.6% of the patients were female (re = 66). Of the patients, 52.9% (n = 45) were using methotrexate (MTX) = hydroxychloroquine (HCQ) +/- corticosteroid (CS), while 43.5% (n = 37) were using anti-tumor necrosis factor center dot (TNF) f MTX. Active steroid usage was ongoing in 64.7% of the patients (n = 55). When evaluated according to DAS-28, in those with higher disease activity, a shorter I-CFT and greater I-MCF were determined (p = 0.020 and p = 0.033, respectively). In those with higher disease activity based on the correlation analysis, I-CFT and E-CFT were shorter and I-MCF and E-MCF were longer, indicating a higher predisposition to thrombosis. Using linear regression, variables with a major effect on ROTEM parameters were identified as DAS-28, CRP, and platelet count. As the first study in the literature, we identified that disease activation is the most important risk factor for prothrombotic state in RA patients irrespective of the drugs used. ROTEM can be used in clinical practice to predict thrombotic events in RA patients.